乳腺癌p53，ki-67和bcl-2的表达与新辅助化疗的关系

目的 研究乳腺癌p53,ki-67和bcl-2基因蛋白表达与新辅助化疗临床效果的关系,以寻找指导治疗、判断预后的生物学指标.方法 采用免疫组化SABC法测定118例可手术的乳腺癌标本的p53,ki-67和bcl-2的蛋白表达,并分析其与新辅助化疗疗效的关系.结果 术前辅助化疗有效率为68.6%.p5 3表达阳性,化疗效果差（P＜0.05）;而ki-67阳性表达者有效率明显高于ki-67不表达者（P＜0.05）;bcl-2表达与疗效无明显关系.p53蛋白阳性表达者bcl-2表达下降.p53与ki-67蛋白表达有明显关系.结论 p53和ki-67蛋白表达可作为指导新辅助化疗及预后判断的分子生物学指标.

p53, ki-67 and bcl-2 expression in breast cancer and its relation to neoadjuvant chemotherapy

Objective To study the correlation of p53, ki-67 and bcl-2 expression in breast cancer with the clinical response to neoadjuvant chemotherapy, and search for biological markers to guide therapy and predict prognosis. Methods The expression of the p53 , ki67 and bcl-2 was examined by immunohistochemical assay in samples of breast cancer tissue which taken from 118 cases of operable breast cancer patients. The relationship between p53, ki-67 and bcl-2 and the effect of neoadjuvant chemotherapy was analyzed by chi-square test. Results The overall response rate to neoadjuvant chemotherapy was 68.6 %. Patients with expression of ki-67 were more likely to respond to treatment. The effect of neoadjuvant chemotherapy had a significantly negative correlation with p53 expression. There was no significant difference between the response to neoadjuvant chemotherapy and bcl-2 expression. Expression of p53 protein was correlated with low expression of bet-2. Expression of p53 and ki-67 protein was significantly related. Conchmions The results indicated that p53 and Ki-67 expressions are strong prognostic molecular markers that can be a guide for neoadjuvant chemotherapy and prediction of prognosis for patients with breast cancer.